

Cholecystectomy During Gastric Bypass Pays Off

BY TIMOTHY F. KIRN
Sacramento Bureau

SAN FRANCISCO — For patients undergoing Roux-en-Y gastric bypass surgery, concurrent cholecystectomy or treatment with ursodiol is more cost-effective than leaving patients alone and waiting to see if they develop gallstones, Dr. Brent C. White reported.

The combined intervention also provides a better quality of life, according to an analysis that he presented at the annual clinical congress of the American College of Surgeons.

Dr. White and his colleagues performed a cost analysis that compared three treatment strategies for patients undergoing Roux-en-Y gastric bypass surgery: Giving ursodiol treatment for 6 months post operatively, performing concurrent cholecystectomy, and watchful waiting for possible gallstones.

'We have to be very careful about the message we are sending when you only look at cost and quality-adjusted life-years' and not issues such as bile duct injury.

The analysis assumed that patients who developed gallstones during watchful waiting or while being treated with ursodiol would undergo cholecystectomy.

After culling information from the peer-reviewed literature, the investigators incorporated into the analysis data on the likelihood of a patient developing gallstones after a Roux-en-Y bypass, on the effectiveness of ursodiol treatment, and on the likelihood of complications with any of the strategies.

In their payer-perspective analysis, the investigators found that concurrent cholecystectomy was the least expensive treatment, with an average cost of \$1,046 per patient, followed by ursodiol at \$2,623 and watchful waiting at \$3,964, said Dr. White of the surgery department at Dartmouth Hitchcock Medical Center, Lebanon, N.H.

The three treatments showed almost the same number of quality-adjusted life-years achieved: 21.39 years for concurrent cholecystectomy, 21.44 years for ursodiol, and 21.43 years for watchful waiting.

When the cost per quality-adjusted life-year of watchful waiting was computed for a population of patients, it was found to exceed the benchmark of what is considered a cost-effective strategy. Ursodiol, on the other hand, was cost-effective, as long as one considered it to be at least 60% effective in preventing gallstones.

On the basis of these findings, Dr. White and his associates concluded that "surgeons who currently employ a watchful waiting approach should consider either using ursodiol or performing a concurrent cholecystectomy."

Studies have suggested that anywhere from 32% to 71% of patients who have a Roux-en-Y bypass will develop gallstones, he noted.

In a 2002 survey of surgeons who perform bariatric procedures, 30% said they use ursodiol treatment after a Roux-en-Y procedure, 15% remove the gallbladder routinely, and the remainder watch and wait, Dr. White said.

The landmark clinical trial of ursodiol treatment found that it reduced the rate of gallstone formation to 2%, from 32% in untreated controls.

In commenting on the analysis, Dr. David Flum said he thought the study was

a timely piece of work, given the variations in practice, but that physicians perhaps should not put too much stock in a study that looked at the issues primarily from a cost perspective.

"We have to be very careful about the message we are sending when you only look at cost and quality-adjusted life-years," said Dr. Flum of the University of Washington, Seattle. Bile duct injury may occur with gallbladder removal, and it has a devastating impact on the patient, he

cautioned. And the situation may be changing as more procedures are done laparoscopically, when removing the gallbladder is more difficult.

Moreover, it is not clear how effective ursodiol treatment is, even when patients are compliant. Studies have shown that patients dislike taking it so much that at least half of them stop.

"I think that a lot of people will take this study and interpret it in different ways," Dr. Flum added. ■

As an adjunct to diet

POWERED...for success

For your broad range of high-risk patients



In 2 separate studies in high-risk patients with diabetes or CAD

More LDL-C reduction than twice the dose of atorvastatin^{1,2}

• 82% of patients with diabetes reached LDL-C goal with a low 10-mg dose without titration¹

Established HDL-C efficacy^{3,4}

• CRESTOR 5 mg to 40 mg increased HDL-C between 8% and 14% (vs 3% with placebo) in patients with primary hypercholesterolemia⁴

Safety in line with other leading statins⁴⁻⁶

• In preapproval clinical trials and postmarketing experience, CRESTOR has demonstrated a safety profile in line with other leading statins⁴⁻⁶

Important Safety Information

- CRESTOR is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, non-HDL-C, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia
- CRESTOR is contraindicated in patients with active liver disease or with unexplained persistent elevations of serum transaminases, in women who are or may become pregnant, and in nursing mothers
- It is recommended that liver function tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (eg, semiannually) thereafter
- The 40-mg dose of CRESTOR is reserved only for those patients who have not achieved their LDL-C goal utilizing the 20-mg dose. Patients initiating statin therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose
- Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with CRESTOR and with other drugs in this class. Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected
- Adverse reactions were usually mild and transient; the most frequent adverse events thought to be related to CRESTOR were myalgia (3.3%), constipation (1.4%), asthenia (1.3%), abdominal pain (1.3%), and nausea (1.3%)^{4,7}
- The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined; long-term outcome studies are currently under way

Please see brief summary of full Prescribing Information on reverse side of this advertisement.



CRESTOR[®]
rosuvastatin calcium